B-cell targeted therapeutics in clinical development
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
B lymphocytes are the source of humoral immunity and are thus a critical component of the adaptive immune system. However, B cells can also be pathogenic and the origin of disease. Deregulated B-cell function has been implicated in several autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis. B cells contribute to pathological immune responses through the secretion of cytokines, costimulation of T cells, antigen presentation, and the production of autoantibodies. DNA-and RNA-containing immune complexes can also induce the production of type I interferons, which further promotes the inflammatory response. B-cell depletion with the CD20 antibody rituximab has provided clinical proof of concept that targeting B cells and the humoral response can result in significant benefit to patients. Consequently, the interest in B-cell targeted therapies has greatly increased in recent years and a number of new biologics exploiting various mechanisms are now in clinical development. This review provides an overview on current developments in the area of B-cell targeted therapies by describing molecules and subpopulations that currently offer themselves as therapeutic targets, the different strategies to target B cells currently under investigation as well as an update on the status of novel therapeutics in clinical development. Emerging data from clinical trials are providing critical insight regarding the role of B cells and autoantibodies in various autoimmune conditions and will guide the development of more efficacious therapeutics and better patient selection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947 · cited 6×
“Th e most relevant activating FcγRs in human are FcγRIIA and FcγRIIIA [37,38].”
BackgroundInfluentialB-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
B cells regulate autoimmunity by provision of IL-10
Fillatreau, S., Sweenie, C. H., McGeachy, M. J., Gray, D., & Anderton, S. M. (2002) · Nature Immunology · doi:10.1038/ni833 · Cited by 1,647
The Immunopathology of Multiple Sclerosis: An Overview
Lassmann, H., Brück, W., & Lucchinetti, C. F. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00064.x · Cited by 1,182
The double life of a B-1 cell: self-reactivity selects for protective effector functions
Baumgarth, N. (2011) · Nature Reviews Immunology · doi:10.1038/nri2901 · Cited by 969
Teeling, J. L. (2004) · Blood · doi:10.1182/blood-2004-01-0039 · Cited by 630
Cytokine-producing B lymphocytes-key regulators of immunity
Lund, F. E. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.03.003 · Cited by 556
Carnahan, J., Stein, R., Qu, Z., Hess, K., Cesano, A., Hansen, H. J., & Goldenberg, D. M. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2006.05.007 · Cited by 175
Rituximab-treated patients have a poor response to influenza vaccination
Eisenberg, R. A., Jawad, A. F., Boyer, J., Maurer, K., McDonald, K., Prak, E. T. L., & Sullivan, K. E. (2013) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9813-x · Cited by 126
Cited by
Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges
Smolen, J. S., & Aletaha, D. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.8 · Cited by 474
Self-citationmiR-155: An Important Role in Inflammation Response
Hu, J., Huang, S., Liu, X., Zhang, Y., Wei, S., & Hu, X. (2022) · Journal of Immunology Research · doi:10.1155/2022/7437281 · Cited by 171
“In addition, a further study proved that in activated CD4 T cells, miR-155 targeted SHIP1 and IFN-gRa to control the severity of stromal keratitis (SK) [66] (Table 1).”
B Cells in Rheumatoid Arthritis: From Pathogenic Players to Disease Biomarkers
Bugatti, S., Vitolo, B., Caporali, R., Montecucco, C., & Manzo, A. (2014) · BioMed Research International · doi:10.1155/2014/681678 · Cited by 170
Hepatic Stellate Cells Directly Inhibit B Cells via Programmed Death–Ligand 1
Li, Y., Lu, L., Qian, S., Fung, J. J., & Lin, F. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501737 · Cited by 29
“, multiple sclerosis and autoimmune uveitis) in which T cells were thought to be the major player in the pathogenesis (35).”
Background
Metadata
- Authors
- Blüml, S., McKeever, K., Ettinger, R., Smolen, J., & Herbst, R.
- Venue
- Arthritis Research & Therapy
- Published
- 2013-03
- Volume
- 15
- Issue
- S1
- Pages
- S4-S4
- ISSN
- 1478-6354 (ISSN-L)
- OpenAlex
- W1977195099
- Cited by
- 110
- References
- 10
- FWCI
- 14.78
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: B-cell targeted therapeutics in clinical development. https://app.cochat.ai/papers/10.1186/ar3906
- The paper
- Blüml, S., McKeever, K., Ettinger, R., Smolen, J., & Herbst, R. (2013). B-cell targeted therapeutics in clinical development. Arthritis Research & Therapy. https://doi.org/10.1186/ar3906
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.